Understanding how mitochondrial DNA damage affects Parkinson's disease
Mechanisms of mitochondrial genome integrity in familial and idiopathic Parkinson's disease
This study is looking at how damage to the tiny powerhouses in our cells, called mitochondria, might play a role in Parkinson's disease, especially for those with a specific gene mutation, and it hopes to find new ways to help improve cell health and slow down the disease, with the help of patients who can share samples.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-10917322 on NIH RePORTER |
What this research studies
This research investigates the role of mitochondrial DNA damage in both familial and idiopathic Parkinson's disease (PD). The study focuses on understanding how mutations in the LRRK2 gene contribute to mitochondrial dysfunction, which is a common feature in PD. By examining the activation of the ATM protein, which is involved in DNA damage repair, the research aims to uncover potential therapeutic targets that could improve mitochondrial health and slow disease progression. Patients may be involved in providing biological samples to help elucidate these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with familial or idiopathic Parkinson's disease, particularly those with known LRRK2 mutations.
Not a fit: Patients with Parkinson's disease caused by other genetic factors or those with non-neurodegenerative conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that not only alleviate symptoms of Parkinson's disease but also address the underlying mitochondrial dysfunction.
How similar studies have performed: Preliminary studies have shown promise in targeting the ATM pathway to mitigate mitochondrial DNA damage in Parkinson's disease, suggesting that this approach may be effective.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: Sanders, Laurie H — Duke University
- Study coordinator: Sanders, Laurie H
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.